/ Unknown statusPhase 1/2 A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma
The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric, gastro-esophageal junction or esophageal adenocarcinoma.
A Phase I, Open Label Study of MBP-426 Given by Intravenous Infusion in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to determine whether MBP-426 (liposomal oxaliplatin suspension for injection) is safe and effective in the treatment of advanced or metastatic solid tumors.
100 Clinical Results associated with Mebiopharm Co., Ltd.
0 Patents (Medical) associated with Mebiopharm Co., Ltd.
100 Deals associated with Mebiopharm Co., Ltd.
100 Translational Medicine associated with Mebiopharm Co., Ltd.